Expression of selected angiogenesis markers and modulators in pre-, periand postmenopausal women with ovarian cancer;Ekspresja wybranych markerów i modulatorów angiogenezy u chorych na raka jajnika w okresie przed-, okołoi pomenopauzalnym

Ginekologia Polska

Volumn 80, Issue 2, 2009, Pages 93-98

  Wiesława, Bednarek ^a   Magdalena, Mazurek ^a   Alicja, Ćwiklińska ^b   Bartłomiej, Barczyński ^a  

^a I Katedra i Klinika Ginekologii Onkologicznej   (Poland)

^b Okregowy Szpital Kolejowy SPZOZ w Lublinie ^*  (Poland)

Author keywords

Antigen human CD105; Antigens CD34; Menopausae; Neovascularization pathologicovarian neoplasms; Receptor epidermal growth factor; Tumor suppressor protein p53

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BIOSYNTHESIS; CANCER STAGING; COMPARATIVE STUDY; FEMALE; HUMAN; MENOPAUSE; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); OVARY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; VASCULARIZATION; WOMEN'S HEALTH;

ADULT; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, CD34; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL; WOMEN'S HEALTH;

EID: 65349156283     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Vasey P. Ovarian cancer: Front-line standard treatment in 2008. Ann Oncol. 2008, 19, Suppl 7, 61-66.
2. Cramer D, Hutchison G, Welch W, [et al.]. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst. 1983, 71, 711-716.
3. Fathalla M. Incessant ovulation-a factor in ovarian neoplasia? Lancet. 1971, 17, 163.
4. Preston-Martin S, Pike M, Ross R, [et al.]. Increased cell division as a cause of human cancer. Cancer Res. 1990, 50, 7415-7421.
5. Prat J, Ribe A, Gallardo A. Hereditary ovarian cancer. Hum Pathol. 2005, 36, 861-870.
6. Junor E, Hole D, Gillis C. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer. 1994, 70, 363-370.
7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971, 285, 1182-1186.
8. Fidlel I, Ellis L. Neoplastic angiogenesisnot all blood vessels are created equal. N Eng J Med. 2004, 351, 215-216.
9. Giatromanolaki A, Sivridis E, Koukourakis M. Tumor angiogenesis: vascular growth and survival. APMIS. 2004, 112, 431-440.
10. Bednarek W. Markers and modulators of angiogenesis in ovarian cancer. Ginekol Pol. 2007, 78, 754-763.
11. Maly Z, Riss P, Deutinger J. Localisation of blood vessels and qualitive assessment of blood flow in ovarian tumors. Obstet Gynecol. 1995, 85, 33-36.
12. Hashizume H, Baluk P, Morikawa S. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000, 156, 1363-1380.
13. Weidner M, Carrol P, Flax J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993, 43, 401-409.
14. Szymański W, Fórmaniak J, Szymański M, [et al.]. Microvessel density index as a prognostic factor in a low histological differentiation stage of endometrial carcinoma. Ginekol Pol. 2002, 73, 951-955.
15. Blok R, Blok K, Jeleń M, [et al.]. Analysis of prognostic factors for the extent of vascularity of serous ovarian cancer on the basis of CD34 antigen expression. Ginekol Pol. 2004, 75, 91-98.
16. Yarden Y. The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities. Eur J Cancer. 2001, 37, Suppl 4, S3-S8.
17. Ellis L. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am. 2004, 18, 1007-1021.
18. Stellmach V, Volpert O, Crawford S, [et al.]. Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts. Eur J Cancer. 1996, 32A, 2394-2400.
19. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Onkology. 2005, 69, Suppl 3, 4-10.
20. Cianchi F, Palomba A, Messerini L, [et al.]. Tumor angiogenesis in lymph node-negative rectal cancer: correlation with clinicopathological parameters and prognosis. Ann Surg Oncol. 2002, 9, 20-26.
21. Dales J, Garcia S, Andrac L, [et al.]. Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome. Int J Oncol. 2004, 24, 1197-1204.
22. Ramakrishnan S, Subramanian I, Yokoyama Y,[et al.]. Angiogenesis in normal and neoplastic ovaries. Angiogenesis. 2005, 8, 169-182.
23. Rossochacka-Rostalska B, Gisterek I, Suder E, [et al.]. Prognostic significance of microvessel density in ovarian cancer. Wiad Lek. 2007, 60, 129-137.
24. Barresi V, Cerasoli S, Vitarelli E, [et al.]. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol. 2007, 114, 147-156.
25. Chan J, Loizzi V, Magistris A, [et al.]. Differences in prognostic molecular markers between women over and under 45 year of age with advanced ovarian cancer. Clin Cancer Res. 2004, 10, 8538-8543.
26. Kaczmarek M. Określenie wieku menopauzy naturalnej w populacji polskich kobiet. Przegla{ogonek}d Menopauzalny. 2007, 2, 77-82.
27. Talley L, Chhieng D, Bell W, [et al.]. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and postmenopausal women. Biotech Histochem. 2008, 83, 5-14.
28. Zavagno G, Meggiolaro F, Pluchinotta A, [et al.]. Influence of age and menopausal status on pathologic and biologic features of breast cancer. Breast. 2000, 9, 320-328.
29. Koshiyama M, Konishi I, Wang D, [et al.]. Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status. Virchows Arch A Pathol Anat Histopathol. 1993, 423, 265-271.
30. Nielsen J, Jakobsen E, Holund B, [et al.]. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer. 2004, 14, 1086-1096.
31. Elie C, Geay J, Morcos M, [et al.]. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GYNECO group). Br J Cancer. 2004, 91, 470-475.
32. Katso R, Manek S, O'Byrne K, [et al.]. Molecular approaches to diagnosis and manegement of ovarian cancer. Cancer Metastasis Rev. 1997, 16, 81-107.
33. Skirnisdottir I, Seidal T, Sorbe B. A new prognostic model comparising p53, EGFR, and tumor grade in early stage epthelial ovarian carcinoma and avoidign the problem of inaccurate surgical staging. Int J Gynecol Cancer. 2004, 14, 259-270.
34. Goff B, Ries J, Els L, [et al.]. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol. 1998, 70, 378-385.
35. Hachisuga T, Hideshima T, Kawarabayashi T, [et al.]. Expression of steroid receptors, Ki67, and epidermal growth factor receptor in tamoxifen-treated endometrium. Int J Gynecol Pathol. 1999, 18, 297-303.
36. Baron A, Cora E, Lafky J, [et al.]. Soluble epidermal growth factor receptor (sEGFR/SerbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2003, 12, 103-113